title: A comparison of two different systems for CD34+ selection of autologous or allogeneic PBSC collections.
abstract: This study compared CD34 selection procedures using the CellPro CEPRATE and the Baxter Isolex 300 systems. Thirty-two procedures were performed, 19 CEPRATE and 13 Isolex. Median starting CD34 percentages were (CEPRATE/Isolex) 0.80% (range 0.24%-7.73%) and 0.85% (range 0.27%-10.17%), respectively (p = 0.788). After selection, there was a highly significant difference in purity of the product (CEPRATE/Isolex), 54% and 82% respectively (p < 0.0001). There was no significant difference in median recovery (CEPRATE/Isolex), 43% and 50%, respectively (p = 0.383). The starting CD34 percentage influenced the purity of the final product, and at high and low starting percentages, the Isolex produced superior purity. Improved efficacy of T cell depletion was observed with the Isolex, a median log depletion of 3.4 compared with 2.9 for the CEPRATE system (p = 0.012). In conclusion, the Isolex 300i produced a significantly higher purity CD34+ fraction, even at starting CD34+ levels of <0.5%, with no significant difference in recovery when compared with the CEPRATE system. The associated log T cell depletion is significantly improved with the Isolex system, with possible implications for use in CD34-selected allogeneic transplants.
authors.affiliation: Department of Haematology, Nottingham City Hospital, Nottingham, UK.
authors.forename: C J
authors.initials: CJ
authors.lastname: Stainer
authors.forename: G
authors.initials: G
authors.lastname: Miflin
authors.forename: S
authors.initials: S
authors.lastname: Anderson
authors.forename: B
authors.initials: B
authors.lastname: Davy
authors.forename: I G
authors.initials: IG
authors.lastname: McQuaker
authors.forename: N H
authors.initials: NH
authors.lastname: Russell
mesh_terms: D019337:Hematologic Neoplasms / Q000628:therapy*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008212:Lymphocyte Depletion / Q000379:methods; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome